← Back to papers

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

★ ★ ★ ★ ☆

Paper Summary

Paperzilla title
Gene Ranking Reveals Top Prognostic Players in Breast Cancer Chemotherapy

By analyzing gene expression data from thousands of breast cancer samples, this study identified and ranked the genes with the highest prognostic power in two clinically relevant cohorts: estrogen receptor-positive/ERBB2-negative patients treated with chemotherapy and basal breast tumors receiving chemotherapy. This ranking helps prioritize promising biomarker candidates for future research and clinical validation.

Explain Like I'm Five

This is like when doctors look for clues to guess how a sick person will get better. Scientists found the most important clues (genes) in thousands of breast cancer samples that help them make the best guess for people.

Possible Conflicts of Interest

None identified

Identified Limitations

Limited Treatment Information
Lack of detailed treatment information, including specific protocols, restricts the depth of analysis and interpretation of chemotherapy response.
Incomplete Clinical Data
The study acknowledges incomplete clinical data for many datasets, limiting the number of samples included in analyses and hindering a comprehensive assessment.
Cohort Specificity
Restricting the analysis to specific cohorts, while necessary for statistical power, may overlook potential biomarkers relevant to other breast cancer subtypes or treatment combinations.
Limited Outcome Measure
The study's focus on relapse-free survival, while clinically relevant, does not fully capture the overall impact of chemotherapy on patient outcomes, such as overall survival or quality of life.

Rating Explanation

This study presents a comprehensive analysis of gene expression data related to breast cancer prognosis, utilizing a large dataset and robust statistical methods. The ranking of genes associated with chemotherapy response in specific cohorts provides a valuable resource for future research and biomarker discovery. While limitations regarding clinical data completeness and treatment information exist, the study's strengths outweigh these weaknesses, warranting a strong rating.

Good to know

This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.

Explore Pro →

File Information

Original Title: Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
Uploaded: July 14, 2025 at 10:44 AM
Privacy: Public